Cancer News
More treatment options for non-small cell lung cancer
The drug Alectinib (Alecensa) received approval by the FDA for the treatment of patients with advanced, metastatic, ALK-positive non-small cell lung cancer.
U.S. approval of an antidote for chemotherapy overdosing
U.S. regulators approved the drug uridine triacetate (Vistogard) for the treatment of overdoses of the chemotherapy drugs fluorouracil and capecitabine.
Breast cancer survival linked to delayed treatment
Delaying treatment and chemotherapy influences the survival rates of breast cancer patients, two large U.S. studies suggest.
Comparing two treatments for common type of breast cancer
Postmenopausal women with ductal carcinoma in-situ treated with anastrozole saw no difference in outcome compared to treatment with tamoxifen.
Is breast-conserving therapy better for breast cancer patients?
Early-stage breast cancer patients who received breast-conserving surgery plus radiation therapy instead of mastectomy lived longer, scientists report.
Sharing symptoms online boosts cancer patients’ survival
Cancer patients who shared their symptoms online improved their quality of life and stayed on treatment longer, a new research points out.
Increased survival for patients with triple-negative breast cancer
Patients with triple-negative breast cancer who had no residual invasive cancer detected after pre-surgery chemotherapy lived longer, scientists discovered.
Adjuvant chemotherapy: not effective for all breast cancer patients
Premenopausal women whose invasive breast cancers were of the luminal A subtype did not benefit from a treatment with adjuvant chemotherapy.
Improved outcomes for breast cancer patients with capecitabine
Breast cancer patients with residual disease after pre-surgery chemotherapy lived longer after being treated with the chemotherapy agent capecitabine.
Combing palbociclib with paclitaxel against advanced breast cancer
The combination of the palbociclib with paclitaxel (Taxol) induced positive patient outcomes when administered to estrogen-receptor positive breast cancer patients.
Denosumab reduces breast cancer relapse rate
The monoclonal antibody (denosumab) given as adjuvant therapy with aromatase inhibitors reduced disease relapse rate in breast cancer patients.
Anxious about getting a genetic cancer screening?
Counseling before and after a genetic cancer screening helped BRCA 1/2-negative patients make informed decisions and deal with anxiety, a new research reveals.
Linking breast cancer treatment and leukemia
Breast cancer survivors at risk of developing leukemia due to chemotherapy and/or radiation share certain characteristics, a new analysis shows.
Experimental drug improves survival in high-risk AML patients
The drug Midostaurin added to standard chemotherapy improved survival in patients with acute myeloid leukemia carrying mutations in the FLT-3 gene, scientists report.
Blinatumomab brings hope to acute lymphoblastic leukemia patients
Blinatumomab proved to be efficient and safe for the treatment of adult patients with acute lymphoblastic leukemia.
Multiple myeloma: improved patient outcomes with combo therapy
Multiple myeloma patients treated with daratumumab combined with standard chemotherapy lived longer without disease progression, a new study finds.
Ixazomib promising for treatment-resistant multiple myeloma
Clinical results reveal the effectiveness of ixazomib plus lenalidomide and dexamethasone in treating patients with relapsed and/or refractory multiple myeloma.
Imbruvica shows better results than chemo in leukemia patients
Chronic lymphocytic leukemia patients decreased more the risk of death when treated with the cancer drug Imbruvica instead of the chemotherapy chlorambucil.
Warfarin: an acceptable treatment for cancer-associated thrombosis
Warfarin can be used for the long-term treatment of cancer-associated thrombosis, in place of standard treatment low-molecular-weight heparin, a new study suggests.
Carfilzomib increased survival rate in relapsed multiple myeloma
Relapsed multiple myeloma patients treated with carfilzomib plus dexamethasone instead of bortezomib plus dexamethasone lived twice as long without disease progression.
Is watchful waiting really included in prostate cancer management?
Scientists reveal that very few low-risk prostate cancer patients followed by watchful waiting are closely monitored as called for in current guidelines.
Best treatment option for breast implant-associated cancer
Complete surgical excision proved to be the best treatment for breast implant-associated anaplastic large-cell lymphoma patients as it led to low recurrence rates.
Depression: a survival predictor in head and neck cancer
A new study reveals that depression has a profound impact on five-year survival and recurrence in head and neck cancer patients.
Antidepressant use and breast-cancer recurrence
No link was identified between risk of recurrence and antidepressant use in breast cancer patients taking an anti-cancer drug and an antidepressant.
Breast cancer: surgery linked to positive patient results
Initial breast surgery was linked to increased and durable survival rates in women with stage IV breast cancer, a new study points out.
Managing stress help women deal with breast cancer
Learning how to manage stress early in their breast cancer treatment helped patients live longer without the disease, a randomized trial shows.
Elotuzumab (Empliciti) gets FDA approval for myeloma
The monoclonal antibody, Elotuzumab, received FDA’s approval to be used for the treatment of myeloma in combination with lenalidomide (Revlimid) and dexamethasone.
EU gets closer to the treatment of Merkel cell carcinoma
European regulators have taken a step closer to the treatment of Merkel cell carcinoma, adopting a positive opinion for Orphan Drug designation for avelumab.
Immuno-oncology treatment for multiple myeloma gets US approval
The FDA approved the immuno-oncology treatment, Empliciti, for the treatment of patients with multiple myeloma.
Soccer counters prostate cancer treatment-related side effects
Prostate cancer patients playing soccer a few times a week improved muscular strength and bone density, tackling treatment-related side effects.